Market Overview

Northern Biologics Strengthens Management Team


Enda Moran appointed vice president, CMC, and Frédéric Sweeney joins
as chief business officer

Northern Biologics Inc., a developer of first-in-class immuno-oncology
products, today announced the appointment of Enda Moran, Ph.D., MBA, as
vice president and head of CMC, and Frédéric Sweeney, Ph.D., as chief
business officer.

"Northern Biologics has recently made an important transition into a
clinical-stage immuno-oncology company. In addition to a promising lead
candidate, MSC-1, in Phase I clinical development and a rich preclinical
pipeline, the quality of the team is essential to the success of our
organization," said Philip Vickers, Ph.D., CEO of Northern Biologics.
"Comprehensive and high-quality CMC packages are one key to our future
success, as is implementing an effective external partnering strategy.
The addition of Enda and Frédéric to the team will ensure rigorous
approaches in both of these important areas. On behalf of the entire
company and its shareholders, I welcome Enda and Frédéric to the
Northern Biologics team and I look forward to working closely with them
at this pivotal stage of our development."

Prior to joining Northern Biologics, Dr. Moran held the position of head
of manufacturing sciences at Pfizer. He has extensive experience leading
biologics and vaccine programs through the clinical development phases
to commercialization, and managing lifecycle changes for commercial
products. He previously held technical leadership positions at both
Wyeth BioPharma and GlaxoSmithKline. He is an inventor on a number of
bioprocess-related patents and has authored numerous peer-reviewed
publications in the fields of bioprocessing and biotechnology.

Dr. Moran obtained his Ph.D. in biochemical engineering at the
University of Wales, UK, and his MBA at IE Business School in Madrid,

Dr. Sweeney's career spans academic research, private and corporate
venture capital as well as operations in small and large companies. Most
recently, he was vice president of corporate development and head of
strategic financing at bioMérieux, a world leader in in vitro
diagnostics. Dr. Sweeney had global responsibilities for new technology
search and evaluation and for bioMérieux's strategic investments.

Prior to bioMérieux, he was head of business development and strategy at
T2 Biosystems, a venture-backed company in the sepsis diagnostics space.
As part of his role at T2 Biosystems, Dr. Sweeney was involved in
private capital raises, establishing key strategic partnerships and the
initial public offering of TTOO on NASDAQ. Dr. Sweeney obtained his BSc
in Biochemistry at McGill University and then completed a Ph.D. focused
on DNA repair, signal transduction and structural biology as a Terry Fox
Scholar at the University of Toronto.

About Northern Biologics

Northern Biologics was launched in June 2014 from Blueline Bioscience, a
Canadian biotechnology incubator operated by venture capital firm
Versant Ventures, in partnership with the University of Toronto and
University Health Network's Princess Margaret Cancer Centre.
Headquartered in the MaRS Discovery District of Toronto, the company is
developing a portfolio of antibody-based therapeutics based on relevant
targets in the tumor microenvironment. Learn more at

View Comments and Join the Discussion!